🔗 Share this article WHO Raises Warning Over Severe Shortage of Obesity Medications Less than one in 10 people eligible to benefit from GLP-1 drugs such as Wegovy have access to them, warns the World Health Organization as it issues its first recommendations on the therapies. With in excess of 1,000,000,000 people worldwide now living with obesity, it is calling for increased and just access to these injectable treatments. According to forecasts, over two billion could be living with obesity by 2030 without intervention. "The latest guidance affirms that obesity is a lifelong illness that can be managed with comprehensive and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and logistical bottlenecks are key obstacles to widespread availability to the jabs that can help people shift significant body mass, explains the body. GLP-1 Therapy Supply Crisis Despite the present best projected outlook, the production of such drugs might only reach about 100 million people – fewer than 10% of eligible patients, as stated by the health organization. The advice urges governments and firms to expand access, via strategies like voluntary licensing. Exclusive production rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026. How Obesity Jabs Work GLP-1 drugs mimick a biological compound to reduce digestion speed, curb appetite and enhance the sense of being full so people reduce food intake. Patients typically begin shedding pounds in the initial weeks of beginning the once-weekly jabs. Evidence indicates patients may regain a significant portion a year later of discontinuing the treatment, because their typical food cravings resume. Being carrying excess weight raises your likelihood for experiencing medical conditions, such as diabetes, heart disease, stroke, and specific cancers. Excess weight impacts people in countries worldwide and was responsible for millions of fatalities worldwide in 2024, per the WHO.
Less than one in 10 people eligible to benefit from GLP-1 drugs such as Wegovy have access to them, warns the World Health Organization as it issues its first recommendations on the therapies. With in excess of 1,000,000,000 people worldwide now living with obesity, it is calling for increased and just access to these injectable treatments. According to forecasts, over two billion could be living with obesity by 2030 without intervention. "The latest guidance affirms that obesity is a lifelong illness that can be managed with comprehensive and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and logistical bottlenecks are key obstacles to widespread availability to the jabs that can help people shift significant body mass, explains the body. GLP-1 Therapy Supply Crisis Despite the present best projected outlook, the production of such drugs might only reach about 100 million people – fewer than 10% of eligible patients, as stated by the health organization. The advice urges governments and firms to expand access, via strategies like voluntary licensing. Exclusive production rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026. How Obesity Jabs Work GLP-1 drugs mimick a biological compound to reduce digestion speed, curb appetite and enhance the sense of being full so people reduce food intake. Patients typically begin shedding pounds in the initial weeks of beginning the once-weekly jabs. Evidence indicates patients may regain a significant portion a year later of discontinuing the treatment, because their typical food cravings resume. Being carrying excess weight raises your likelihood for experiencing medical conditions, such as diabetes, heart disease, stroke, and specific cancers. Excess weight impacts people in countries worldwide and was responsible for millions of fatalities worldwide in 2024, per the WHO.